Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2019 to Jul 2024
GammaCan International (OTC BB:GCAN), a developer of
immunotherapies for cancer and other diseases, today announced that
Patrick Schnegelsberg, Chief Executive Officer, will provide a company
overview at the Rodman & Renshaw 3rd Annual Global Healthcare
Conference on Tuesday, May 16 at 8:40 am CEST in Monte Carlo, Monaco.
Patrick Schnegelsberg, GammaCan International's recently appointed
CEO will provide an update on the Company's pipeline to treat cancer
and introduce VitiGam, GammaCan's lead program to treat malignant
melanoma.
To access the live webcast, please go to www.GammaCan.com and
click on the "Investor Relations" link. The replay will be available
for approximately one week following the presentation.
About VitiGam:
VitiGam is a second generation IVIg product and a first-in-class
anti-cancer immunotherapy. GammaCan plans on having VitiGam to enter
phase I/II testing under a US IND in the near future and the Company
recently held a pre-IND meeting with the FDA. VitiGam is being
designed to target metastatic melanoma patients with Stage 3 and 4
melanoma. VitiGam is an IVIg product that is different from standard
IVIg: It is manufactured from the plasma of donors with vitiligo, a
benign autoimmune skin condition affecting up to 2% of the general
population. GammaCan scientists have shown that this "enriched"
vitiligo IVIg (VitiGam) contains potent anti-melanoma activity in both
in vitro and mouse xenograft melanoma models. Thus, GammaCan expects
VitiGam to provide (1) anti-melanoma activity directed specifically
against malignant melanoma cells and (2) non-specific anti-cancer
activity - as is the case with IVIg in general.
About GammaCan:
GammaCan is focusing on the commercialization of an innovative
anti-cancer immunotherapy to treat metastatic cancer. GammaCan's
platform is based on IVIg, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. IVIg works by strengthening the
patient's immune system. Many experts currently view immunotherapy as
a future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an IVIg
derived from the plasma of vitiligo donors and is being developed to
treat malignant melanoma. GammaCan owns, and has applied for US patent
protection covering the use of IVIg and vitiligo-derived IVIg
(VitiGam). For more information about GammaCan visit www.GammaCan.com
or call the company's headquarters in Givat Shmuel, Israel at 972 3
5774475 or toll free 1-866-308-0396 (from North America).
Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding: the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IVIg into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties
such as the inability to finance the planned development of the
technology, inability to hire appropriate staff to develop the
technology, unforeseen technical difficulties in developing the
technology, inability to obtain regulatory approval for human use,
competitors' therapies proving more effective, cheaper or otherwise
preferable for consumers, inability to market the product we produce,
among other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further risk
factors see the risk factors associated with other early stage medical
research and development companies filed with the SEC on EDGAR.